ABSTRACT
BACKGROUND: Tuberculosis (TB) continues to be the most frequent cause of illness and death from an infectious agent globally, and its interaction with HIV is having devastating effects. To investigate how HIV alters the immune response to Mycobacterium tuberculosis (Mtb), we assessed basal and Mtb-induced proliferation, cytokine production, and expression of signalling lymphocytic activation molecule (SLAM), inducible costimulator (ICOS) and programmed death-1 (PD-1) on T lymphocytes from HIV-positive individuals coinfected with TB, HIV-positive subjects, TB patients and healthy donors (HD). FINDINGS: HIV-TB patients showed increased ICOS, SLAM and PD-1 basal levels on T lymphocytes, whereas HIV-positive individuals displayed elevated levels of SLAM and PD-1, TB patients high levels of SLAM, and HD low levels of the three proteins. Mtb-stimulation enhanced ICOS expression in the four groups, but only TB and HD increased SLAM and PD-1 levels. CONCLUSIONS: These data show the immune deregulation that takes place during the immune response against TB in different study populations.
Subject(s)
Antigens, CD/biosynthesis , Gene Expression Profiling , HIV Infections/complications , Inducible T-Cell Co-Stimulator Protein/biosynthesis , Programmed Cell Death 1 Receptor/biosynthesis , Receptors, Cell Surface/biosynthesis , T-Lymphocytes/immunology , Tuberculosis, Pulmonary/immunology , Cell Proliferation , Cytokines/metabolism , Humans , Signaling Lymphocytic Activation Molecule Family Member 1 , T-Lymphocytes/chemistryABSTRACT
The monocyte chemotactic protein-1 (MCP-1) is a chemokine that plays an important role in the recruitment of monocytes to M. tuberculosis infection sites, and previous studies have reported that genetic variants in MCP1 are associated with differential susceptibility to pulmonary tuberculosis (PTB). We examined eight MCP1 single nucleotide polymorphisms (SNPs) in a multi-ethnic, case-control design that included: 321 cases and 346 controls from Guinea-Bissau, 258 cases and 271 controls from The Gambia, 295 cases and 179 controls from the U.S. (African-Americans), and an additional set of 237 cases and 144 controls of European ancestry from the U.S. and Argentina. Two locus interactions were also examined for polymorphisms in MCP1 and interleukin 12B (IL12B), another gene implicated in PTB risk. Examination of previously associated MCP1 SNPs rs1024611 (-2581A/G), rs2857656 (-362G/C) and rs4586 (+900C/T) did not show evidence for association. One interaction between rs2857656 and IL12B SNP rs2288831 was observed among Africans but the effect was in the opposite direction in Guineans (OR = 1.90, p = 0.001) and Gambians (OR = 0.64, p = 0.024). Our data indicate that the effect of genetic variation within MCP1 is not clear cut and additional studies will be needed to elucidate its role in TB susceptibility.
Subject(s)
Chemokine CCL2/genetics , Epistasis, Genetic , Interleukin-12 Subunit p40/genetics , Polymorphism, Genetic , Tuberculosis, Pulmonary/diagnosis , Tuberculosis, Pulmonary/genetics , Adolescent , Adult , Black or African American , Aged , Argentina , Black People , Case-Control Studies , Chemokine CCL2/biosynthesis , Ethnicity , Female , Gambia , Genetic Predisposition to Disease , Genetic Variation , Guinea-Bissau , Humans , Male , Middle Aged , United States , White PeopleABSTRACT
OBJECTIVES: Current drug choices to treat extensively drug-resistant (XDR) tuberculosis (TB) are scarce; therefore, information on the safety, tolerability and efficacy of alternative regimens is of utmost importance. The aim of this study was to describe the management, drug adverse effects and outcome of alternative combined treatment in a series of XDR-TB patients. PATIENTS AND METHODS: A retrospective study was performed on 17 non-AIDS, pulmonary adult patients with XDR-TB admitted to a referral treatment centre for infectious diseases in Buenos Aires from 2002 through 2008. Drug susceptibility testing was performed under regular proficiency testing and confirmed at the national TB reference laboratory. RESULTS: Linezolid was included in the drug regimens of all patients; moxifloxacin and/or thioridazine were included in the regimens of 14 patients. Clinically tractable drug adverse effects were observed in nine patients, the most frequent being haematological disorders and neurotoxicity. In two patients, thioridazine was discontinued. Negative culture conversion was achieved in 15 patients, 11 completed treatment meeting cure criteria, 4 are still on follow-up with good evolution, 1 defaulted treatment and 1 was lost to follow-up. CONCLUSIONS: The combination of linezolid, moxifloxacin and thioridazine is recommended for compassionate use in specialized centres with expertise in the management of XDR-TB.
Subject(s)
Acetamides/administration & dosage , Antitubercular Agents/administration & dosage , Aza Compounds/administration & dosage , Extensively Drug-Resistant Tuberculosis/drug therapy , Oxazolidinones/administration & dosage , Quinolines/administration & dosage , Thioridazine/administration & dosage , Acetamides/adverse effects , Adult , Antitubercular Agents/adverse effects , Argentina , Aza Compounds/adverse effects , Compassionate Use Trials/methods , Drug Resistance, Multiple, Bacterial , Extensively Drug-Resistant Tuberculosis/microbiology , Female , Fluoroquinolones , Humans , Linezolid , Male , Middle Aged , Moxifloxacin , Mycobacterium tuberculosis/drug effects , Mycobacterium tuberculosis/isolation & purification , Oxazolidinones/adverse effects , Quinolines/adverse effects , Retrospective Studies , Thioridazine/adverse effects , Treatment Outcome , Tuberculosis, Pulmonary/drug therapy , Tuberculosis, Pulmonary/microbiologyABSTRACT
BACKGROUND: The proinflammatory cytokine interleukin 17 (IL-17) plays an important role in immune responses but it is also associated with tissue-damaging inflammation. So, we evaluated the ability of Mycobacterium tuberculosis clinical isolates to induce IL-17 in tuberculosis (TB) patients and in healthy human tuberculin reactors (PPD(+)HD). METHODS: IL-17, interferon γ (IFN-γ), and interleukin 23 (IL-23) receptor expression were evaluated ex vivo and cultured peripheral blood mononuclear cells from TB and PPD(+)HD stimulated with irradiated clinical isolates from multidrug resistant (MDR) outbreaks M (Haarlem family) and Ra (Latin American-Mediterranean family), as well as drug-susceptible isolates belonging to the same families and laboratory strain H37Rv for 48 hours in T-cell subsets by flow cytometry. RESULTS: We observed that: (1) MDR strains M and Ra are stronger IL-17 inducers than drug-susceptible Mtb strains of the Haarlem and Latin American-Mediterranean families, (2) MDR-TB patients show the highest IL-17 expression that is independent on the strain, (3) IL-17 expression is dependent on CD4(+) and CD8(+) T cells associates with persistently high antigen load. CONCLUSIONS: IL-17--producing T cells could play an immunopathological role in MDR-TB promoting severe tissue damage, which may be associated with the low effectiveness of the second-line drugs employed in the treatment.
Subject(s)
Antigens, Bacterial/immunology , CD4-Positive T-Lymphocytes/metabolism , CD8-Positive T-Lymphocytes/metabolism , Mycobacterium tuberculosis/immunology , T-Lymphocyte Subsets/immunology , Tuberculosis, Multidrug-Resistant/immunology , Adult , Cells, Cultured , Female , Humans , Interferon-gamma/metabolism , Interleukin-17/metabolism , Male , Middle Aged , Receptors, Antigen, T-Cell, gamma-delta/immunology , Receptors, Antigen, T-Cell, gamma-delta/metabolism , Receptors, Interleukin/metabolism , T-Lymphocyte Subsets/metabolism , Young AdultABSTRACT
The role of CD16(-) and CD16(+) Mo subsets in human TB remains unknown. Our aim was to characterize Mo subsets from TB patients and to assess whether the inflammatory milieu from TB pleurisy modulate their phenotype and recruitment. We found an expansion of peripheral CD16(+) Mo that correlated with disease severity and with TNF-α plasma levels. Circulating Mo from TB patients are activated, showing a higher CD14, CD16, and CD11b expression and Mtb binding than HS. Both subsets coexpressed CCR2/CCR5, showing a potential ability to migrate to the inflammatory site. In tuberculous PF, the CD16(+) subset was the main Mo/MΦ population, accumulation that can be favored by the induction of CD16 expression in CD16(-) Mo triggered by soluble factors found in this inflammatory milieu. CD16(+) Mo in PF were characterized by a high density of receptors for Mtb recognition (DC-SIGN, MR, CD11b) and for lipid-antigens presentation (CD1b), allowing them to induce a successful, specific T cell proliferation response. Hence, in tuberculous PF, CD16(+) Mo constitute the main APC population; whereas in PB, their predominance is associated with the severity of pulmonary TB, suggesting a paradoxical role of the CD16(+) Mo subset that depends on the cellular localization.
Subject(s)
Monocytes/immunology , Receptors, CCR2/analysis , Receptors, CCR5/analysis , Receptors, IgG/analysis , Tuberculosis, Pleural/immunology , Tuberculosis/immunology , Adult , Aged , Antigen-Presenting Cells/immunology , Antigen-Presenting Cells/metabolism , Cell Separation , Cytokines/analysis , Cytokines/blood , Enzyme-Linked Immunosorbent Assay , Female , Flow Cytometry , GPI-Linked Proteins/analysis , GPI-Linked Proteins/immunology , GPI-Linked Proteins/metabolism , Humans , Male , Middle Aged , Monocytes/metabolism , Pleural Effusion/immunology , Pleural Effusion/metabolism , Receptors, CCR2/immunology , Receptors, CCR2/metabolism , Receptors, CCR5/immunology , Receptors, CCR5/metabolism , Receptors, IgG/immunology , Receptors, IgG/metabolism , Tuberculosis/metabolism , Tuberculosis, Pleural/metabolismABSTRACT
We examined whether polymorphisms in interleukin-12B (IL12B) associate with susceptibility to pulmonary tuberculosis (PTB) in two West African populations (from The Gambia and Guinea-Bissau) and in two independent populations from North and South America. Nine polymorphisms (seven SNPs, one insertion/deletion, one microsatellite) were analyzed in 321 PTB cases and 346 controls from Guinea-Bissau and 280 PTB cases and 286 controls from The Gambia. For replication we studied 281 case and 179 control African-American samples and 221 cases and 144 controls of European ancestry from the US and Argentina. First-stage single locus analyses revealed signals of association at IL12B 3' UTR SNP rs3212227 (unadjusted allelic pâ=â0.04; additive genotypic pâ=â0.05, ORâ=â0.78, 95% CI [0.61-0.99]) in Guinea-Bissau and rs11574790 (unadjusted allelic pâ=â0.05; additive genotypic pâ=â0.05, ORâ=â0.76, 95% CI [0.58-1.00]) in The Gambia. Association of rs3212227 was then replicated in African-Americans (rs3212227 allelic pâ=â0.002; additive genotypic pâ=â0.05, ORâ=â0.78, 95% CI [0.61-1.00]); most importantly, in the African-American cohort, multiple significant signals of association (seven of the nine polymorphisms tested) were detected throughout the gene. These data suggest that genetic variation in IL12B, a highly relevant candidate gene, is a risk factor for PTB in populations of African ancestry, although further studies will be required to confirm this association and identify the precise mechanism underlying it.
Subject(s)
Genetic Variation , Interleukin-12 Subunit p40/genetics , Tuberculosis, Pulmonary/genetics , Adolescent , Adult , Aged , Aged, 80 and over , Argentina/epidemiology , Black People/genetics , Case-Control Studies , Cohort Studies , Female , Gambia/epidemiology , Gene Frequency , Genetic Association Studies , Genetic Variation/physiology , Genetics, Population , Guinea-Bissau/epidemiology , Humans , Linkage Disequilibrium , Male , Middle Aged , Polymorphism, Single Nucleotide/physiology , Tuberculosis, Pulmonary/epidemiology , Tuberculosis, Pulmonary/ethnology , United States/epidemiology , Young AdultABSTRACT
La tuberculosis extensamente resistente a múltiples drogas (XDR-TB), resistente a isoniacida, rifampicina, alguna fluoroquinolona y al menos una entre kanamicina, amikacina, o capreomicina; ha sido descripta en la mayoría de las regiones del mundo con efectos devastadores. Por esta razón, la información sobre seguridad, tolerabilidad y eficacia acerca de drogas potencialmente útiles en su tratamiento es de extrema utilidad, no sólo para mejorar el pronóstico individual de estos pacientes sino también para controlar su diseminación. Se presentan 18 casos de localización pulmonar en pacientes sin Sida. Se trataron con esquemas que incluyeron en todos los casos linezolida; en 13, moxifloxacina, y en 13, tioridazina, todos negativizaron al examen directo y cultivo del esputo. Once pacientes cumplieron criterios de curación, 6 están aún en tratamiento y 3 abandonaron. Diez pacientes presentaron efectos adversos, en sólo 1 caso debió suspenderse la tioridazina. La utilización de linezolid, moxifloxacina y tioridazina ha contribuído a la evolución satisfactoria de estos pacientes. Estos fármacos son considerados de utilidad en esta serie, pero deben ser empleados en centros especializados con experiencia en el manejo de la XDR-TB.
Subject(s)
Humans , Male , Female , Therapeutic Uses , Argentina , Mycobacterium tuberculosis , Tuberculosis, Multidrug-Resistant/epidemiology , Tuberculosis, Multidrug-Resistant/drug therapy , Tuberculosis, Multidrug-Resistant/therapyABSTRACT
La tuberculosis extensamente resistente a múltiples drogas (XDR-TB), resistente a isoniacida, rifampicina, alguna fluoroquinolona y al menos una entre kanamicina, amikacina, o capreomicina; ha sido descripta en la mayoría de las regiones del mundo con efectos devastadores. Por esta razón, la información sobre seguridad, tolerabilidad y eficacia acerca de drogas potencialmente útiles en su tratamiento es de extrema utilidad, no sólo para mejorar el pronóstico individual de estos pacientes sino también para controlar su diseminación. Se presentan 18 casos de localización pulmonar en pacientes sin Sida. Se trataron con esquemas que incluyeron en todos los casos linezolida; en 13, moxifloxacina, y en 13, tioridazina, todos negativizaron al examen directo y cultivo del esputo. Once pacientes cumplieron criterios de curación, 6 están aún en tratamiento y 3 abandonaron. Diez pacientes presentaron efectos adversos, en sólo 1 caso debió suspenderse la tioridazina. La utilización de linezolid, moxifloxacina y tioridazina ha contribuído a la evolución satisfactoria de estos pacientes. Estos fármacos son considerados de utilidad en esta serie, pero deben ser empleados en centros especializados con experiencia en el manejo de la XDR-TB.(AU)
Subject(s)
Humans , Male , Female , Tuberculosis, Multidrug-Resistant/therapy , Tuberculosis, Multidrug-Resistant/epidemiology , Tuberculosis, Multidrug-Resistant/drug therapy , Mycobacterium tuberculosis , Therapeutic Uses , ArgentinaABSTRACT
Tuberculous pleurisy allows the study of specific cells at the site of Mycobacterium tuberculosis infection. Among pleural lymphocytes, natural killer (NK) cells are a major source of interferon gamma (IFN-gamma), and their functions are regulated by activating and inhibitory receptors. Programmed death-1 (PD-1), programmed death ligand 1 (PD-L1), and programmed death ligand 2 (PD-L2) are recognized inhibitory receptors in adaptive immunity, but their role during innate immunity remains poorly understood. We investigated the PD-1:PD-L1/PD-L2 pathway on NK cell effector functions in peripheral blood and pleural fluid from patients with tuberculosis. M. tuberculosis stimulation significantly up-regulated PD-1, PD-L1, and PD-L2 levels on NK cells. Interestingly, a direct correlation between PD-1 and IFN-gamma expression on NK cells was observed. Moreover, blockade of the PD-1 pathway markedly augmented lytic degranulation and IFN-gamma production of NK cells against M. tuberculosis. Furthermore, PD-1(+) NK cells displayed a diminished IFN-gamma mean fluorescence intensity, denoting the relevance of PD-1 on IFN-gamma regulation. Together, we described a novel inhibitory role played by PD-1:PD-L interactions in innate immunity in tuberculosis.
Subject(s)
Antigens, CD/immunology , Apoptosis Regulatory Proteins/immunology , Apoptosis , Immunity, Innate , Mycobacterium tuberculosis/immunology , Tuberculosis/immunology , Tuberculosis/pathology , Adult , B7-H1 Antigen , Blood/immunology , Gene Expression Profiling , Humans , Intercellular Signaling Peptides and Proteins/immunology , Interferon-gamma/antagonists & inhibitors , Interferon-gamma/metabolism , Killer Cells, Natural/immunology , Pleura/immunology , Programmed Cell Death 1 Ligand 2 Protein , Programmed Cell Death 1 Receptor , Up-RegulationABSTRACT
During a chronic infection such as tuberculosis, the pool of tissue dendritic cells (DC) must be renewed by recruitment of both circulating DC progenitors and monocytes (Mo). However, the microenvironment of the inflammatory site affects Mo differentiation. As DC are critical for initiating a Mycobacterium tuberculosis-specific T-cell response, we argue that interference of M. tuberculosis with a correct DC generation would signify a mechanism of immune evasion. In this study, we showed that early interaction of γ-irradiated M. tuberculosis with Mo subverts DC differentiation in vitro. We found that irradiated M. tuberculosis effect involves (1) the loss of a significant fraction of monocyte population and (2) an altered differentiation process of the surviving monocyte subpopulation. Moreover, in the absence of irradiated M. tuberculosis, DC consist in a major DC-specific intercellular adhesion molecule 3-grabbing non-integrin receptor (DC-SIGN(high))/CD86(low) and minor DC-SIGN(low)/CD86(high) subpopulations, whereas in the presence of bacteria, there is an enrichment of DC-SIGN(low)/CD86(high) population. Besides, this population enlarged by irradiated M. tuberculosis, which is characterized by a reduced CD1b expression, correlates with a reduced induction of specific T-lymphocyte proliferation. The loss of CD1molecules partially involves toll-like receptors (TLR-2)/p38 MAPK activation. Finally, several features of Mo, which have been differentiated into DC in the presence of irradiated M. tuberculosis, resemble the features of DC obtained from patients with active tuberculosis. In conclusion, we suggest that M. tuberculosis escapes from acquired immune response in tuberculosis may be caused by an altered differentiation into DC leading to a poor M. tuberculosis-specific T-cell response.
Subject(s)
Dendritic Cells/immunology , Dendritic Cells/microbiology , Adult , Antigens, CD1/metabolism , B7-2 Antigen/metabolism , Cell Adhesion Molecules/metabolism , Cell Differentiation/immunology , Cell Proliferation , Cells, Cultured , Humans , Interleukin-10/metabolism , Lectins, C-Type/metabolism , Lymphocyte Culture Test, Mixed , Macrophages/immunology , Mannose Receptor , Mannose-Binding Lectins/metabolism , Middle Aged , Mycobacterium tuberculosis/pathogenicity , Receptors, Cell Surface/metabolism , Toll-Like Receptor 2/metabolism , Tuberculosis/immunology , Tuberculosis/physiopathology , p38 Mitogen-Activated Protein Kinases/metabolismABSTRACT
Tuberculosis (TB) is a global public health problem and a source of preventable deaths each year, with 8.8 million new cases of TB and 1.6 million deaths worldwide in 2005. Approximately, 10% of infected individuals develop pulmonary or extrapulmonary TB, suggesting that host defense factors influence development of active disease. Toll-like receptor' (TLR) polymorphisms have been associated with regulation of TLR expression and development of active TB. In the present study, 71 polymorphisms in TLR1, TLR2, TLR4, TLR6, and TLR9 were examined from 474 (295 cases and 179 controls) African-Americans, 381 (237 cases and 144 controls) Caucasians, and from 667 (321 cases and 346 controls) Africans from Guinea-Bissau for association with pulmonary TB using generalized estimating equations and logistic regression. Statistically significant associations were observed across populations at TLR9 and TLR2. The strongest evidence for association came at an insertion (I)/deletion (D) polymorphism (-196 to -174) in TLR2 that associated with TB in both Caucasians (II vs. ID&DD, OR = 0.41 [95% CI 0.24-0.68], p = 0.0007) and Africans (II vs. ID&DD, OR = 0.70 [95% CI 0.51-0.95], p = 0.023). Our findings in three independent population samples indicate that variations in TLR2 and TLR9 might play important roles in determining susceptibility to TB.
Subject(s)
Black People/genetics , Black or African American/genetics , Toll-Like Receptor 2/genetics , Toll-Like Receptor 9/genetics , Tuberculosis, Pulmonary/genetics , White People/genetics , Gene Frequency , Genetic Predisposition to Disease , Genetic Variation , Genotype , Guinea-Bissau , Humans , Linkage Disequilibrium , Polymorphism, Single Nucleotide , Tuberculosis, Pulmonary/ethnology , United StatesABSTRACT
Tuberculous pleurisy, one of the most common manifestations of extrapulmonary tuberculosis, is characterized by a T-cell-mediated hypersensitivity reaction along with a Th1 immune profile. In this study, we investigated functional cross-talk among T and NK cells in human tuberculous pleurisy. We found that endogenously activated pleural fluid-derived NK cells express high ICAM-1 levels and induce T-cell activation ex vivo through ICAM-1. Besides, upon in vitro stimulation with monokines and PAMP, resting peripheral blood NK cells increased ICAM-1 expression leading to cellular activation and Th1 polarization of autologous T cells. Furthermore, these effects were abolished by anti-ICAM-1 Ab. Hence, NK cells may contribute to the adaptive immune response by a direct cell-contact-dependent mechanism in the context of Mycobacterium tuberculosis infection.
Subject(s)
Intercellular Adhesion Molecule-1/metabolism , Killer Cells, Natural/immunology , Mycobacterium tuberculosis , T-Lymphocytes/immunology , Tuberculosis, Pleural/immunology , Adult , CD11a Antigen/immunology , CD56 Antigen/immunology , Cell Communication/immunology , Cysteine/analogs & derivatives , Cysteine/pharmacology , Humans , Intercellular Adhesion Molecule-1/drug effects , Intercellular Adhesion Molecule-1/immunology , Interleukin-12/pharmacology , Interleukin-15/pharmacology , Interleukin-18/pharmacology , Lipopolysaccharides/pharmacology , Lipoproteins/pharmacology , Middle Aged , Phosphotransferases (Phosphate Group Acceptor)ABSTRACT
Tuberculosis (TB) has substantial mortality worldwide with 5-10% of those exposed progressing to active TB disease. Studies in mice and humans indicate that the inducible nitric oxide synthase (iNOS) molecule plays an important role in immune response to TB. A mixed case-control association study of individuals with TB, relatives, or close contact controls was performed in 726 individuals (279 case and 166 control African-Americans; 198 case and 123 control Caucasians). Thirty-nine single nucleotide polymorphisms (SNPs) were selected from the NOS2A gene for single SNP, haplotype, and multilocus interaction analyses with other typed candidate genes using generalized estimating equations. In African-Americans, ten NOS2A SNPs were associated with TB. The strongest associations were observed at rs2274894 (odds ratio (OR) = 1.84, 95% confidence interval (CI) [1.23-2.77], p = 0.003) and rs7215373 (OR = 1.67, 95% CI [1.17-2.37], p = 0.004), both of which passed a false discovery rate correction for multiple comparisons (q* = 0.20). The strongest gene-gene interactions were observed between NOS2A rs2248814 and IFNGR1 rs1327474 (p = 0.0004) and NOS2A rs944722 and IFNGR1 rs1327474 (p = 0.0006). Three other SNPs in NOS2A interacted with TLR4 rs5030729 and five other NOS2A SNPs interacted with IFNGR1 rs1327474. No significant associations were observed in Caucasians. These results suggest that NOS2A variants may contribute to TB susceptibility, particularly in individuals of African descent, and may act synergistically with SNPs in TLR4 and IFNGR1.
Subject(s)
Black People/genetics , Genetic Predisposition to Disease , Nitric Oxide Synthase Type II/genetics , Polymorphism, Single Nucleotide , Receptors, Interferon/genetics , Toll-Like Receptor 4/genetics , Tuberculosis, Pulmonary/genetics , Adolescent , Adult , Case-Control Studies , Child , Chromosome Mapping , Exons/genetics , Family , Female , Genotype , Humans , Introns , Male , Models, Genetic , Promoter Regions, Genetic , United States/epidemiology , White People/genetics , Interferon gamma ReceptorABSTRACT
Capítulo 1: La TB constituye un grave problema de salud pública aún no resuelto y una enfermedad marcadora de pobreza: el 95% de los casos se registra en países en vías de desarrollo y un 98% de las muertes se observa también en esos países. En nuestro país, en el 2006 ha habido 11.068 casos de tuberculosis, lo que representa una tasa de 28,4 casos por cada 100.000 habitantes. La necesidad de un Programa de Control de TB (PCT) implica una política de salud que responda a una estrategia nacional descentralizada y horizontal, donde el Estado asuma su responsabilidad indelegable como controlador, regulador, dispensador, promotor y rehabilitador de la salud de la población. El primer objetivo de todo PCT es el diagnóstico precoz y un adecuado tratamiento de los casos de TB. La isoniacida continúa siendo la droga de elección, avalada por 50 años de experiencia. La vacuna conocida como BCG sólo se administra una única dosis al nacer ó hasta los seis años si el niño no tiene certificado de vacunación ni cicatriz. Capítulo 2: La tuberculosis en trabajadores de la salud constituye un grave problema de salud pública. Los factores de los que depende que un individuo se infecte son: la concentración de gotas infectantes en el aire, el número de recambio del volumen de aire en el ambiente y el tiempo de exposición. Para implementar un programa para la prevención y tratamiento de la TB se deben implementar medidas administrativas o de gestión, medidas de control ambiental y medidas de protección respiratoria personal. Las medidas administrativas incluyen asignación de responsabilidades para el control, evaluación y mantenimiento del programa, evaluación del riesgo y desarrollo del plan de control, identificación de los pacientes susceptibles de padecer tuberculosis, manejo del paciente hospitalizado, educación, entrenamiento y asesoramiento sobre tuberculosis a los integrantes del equipo de salud. Las medidas de control ambiental incluyen tecnologías para remover ...
Subject(s)
Adolescent , Adult , Child , Middle Aged , BCG Vaccine , Mycobacterium tuberculosis , Tuberculosis/diagnosis , Tuberculosis/epidemiology , Tuberculosis/prevention & control , Tuberculosis/drug therapy , Tuberculosis/therapy , Argentina , Antitubercular Agents/administration & dosage , Antitubercular Agents/therapeutic use , ConsensusSubject(s)
Humans , Male , Adult , Pleural Diseases/surgery , Pleural Diseases/diagnosis , Pleural Diseases/pathology , Pleural Diseases , Pleural Effusion , Antitubercular Agents/pharmacology , Asbestos/adverse effects , Biopsy, Needle , Mesothelioma , Lung/pathology , Tuberculosis/etiology , Tuberculosis/therapyABSTRACT
Capítulo 1: La TB constituye un grave problema de salud pública aún no resuelto y una enfermedad marcadora de pobreza: el 95% de los casos se registra en países en vías de desarrollo y un 98% de las muertes se observa también en esos países. En nuestro país, en el 2006 ha habido 11.068 casos de tuberculosis, lo que representa una tasa de 28,4 casos por cada 100.000 habitantes. La necesidad de un Programa de Control de TB (PCT) implica una política de salud que responda a una estrategia nacional descentralizada y horizontal, donde el Estado asuma su responsabilidad indelegable como controlador, regulador, dispensador, promotor y rehabilitador de la salud de la población. El primer objetivo de todo PCT es el diagnóstico precoz y un adecuado tratamiento de los casos de TB. La isoniacida continúa siendo la droga de elección, avalada por 50 años de experiencia. La vacuna conocida como BCG sólo se administra una única dosis al nacer ó hasta los seis años si el niño no tiene certificado de vacunación ni cicatriz. Capítulo 2: La tuberculosis en trabajadores de la salud constituye un grave problema de salud pública. Los factores de los que depende que un individuo se infecte son: la concentración de gotas infectantes en el aire, el número de recambio del volumen de aire en el ambiente y el tiempo de exposición. Para implementar un programa para la prevención y tratamiento de la TB se deben implementar medidas administrativas o de gestión, medidas de control ambiental y medidas de protección respiratoria personal. Las medidas administrativas incluyen asignación de responsabilidades para el control, evaluación y mantenimiento del programa, evaluación del riesgo y desarrollo del plan de control, identificación de los pacientes susceptibles de padecer tuberculosis, manejo del paciente hospitalizado, educación, entrenamiento y asesoramiento sobre tuberculosis a los integrantes del equipo de salud. Las medidas de control ambiental incluyen tecnologías para remover ... (AU)
Subject(s)
Adolescent , Adult , Child , Middle Aged , Aged , Mycobacterium tuberculosis/drug effects , Tuberculosis/diagnosis , Tuberculosis/drug therapy , Tuberculosis/epidemiology , Tuberculosis/prevention & control , Tuberculosis/therapy , BCG Vaccine , Antitubercular Agents/administration & dosage , Antitubercular Agents/therapeutic use , Argentina , ConsensusSubject(s)
Humans , Male , Adult , Pleural Effusion , Pleural Diseases/diagnosis , Pleural Diseases/pathology , Pleural Diseases/diagnostic imaging , Pleural Diseases/surgery , Asbestos/adverse effects , Antitubercular Agents/pharmacology , Biopsy, Needle , Mesothelioma , Lung/pathology , Tuberculosis/etiology , Tuberculosis/therapyABSTRACT
RATIONALE: Human secretory leukocyte protease inhibitor (SLPI) displays bactericidal activity against pathogens such as Escherichia coli and Streptococcus. Furthermore, it has been reported that murine SLPI shows potent antimycobacterial activity. OBJECTIVES: The aim of the present study was to investigate whether human recombinant SLPI not only kills mycobacteria but also acts as a pattern recognition receptor for the host immune system. METHODS: For the in vivo experiment, BALB/c mice were infected by intranasal instillation with Mycobacterium bovis BCG and viable BCG load in lung homogenates was later determined. For the in vitro experiments, SLPI was incubated overnight with a suspension of M. bovis BCG or the virulent strain Mycobacterium tuberculosis H37Rv, and the percentage survival as well as the binding of SLPI to mycobacteria was determined. Furthermore, bacteria phagocytosis was also determined by flow cytometry. MEASUREMENTS AND MAIN RESULTS: Intranasal SLPI treatment decreased the number of colony-forming units recovered from lung homogenates, indicating that SLPI interfered with M. bovis BCG infection. Moreover, SLPI decreased the viability of both M. bovis BCG and H37Rv. We demonstrated that SLPI attached to the surface of the mycobacteria by binding to pathogen-associated molecular pattern mannan-capped lipoarabinomannans and phosphatidylinositol mannoside. Furthermore, we found that in the sputum of patients with tuberculosis, mycobacteria were coated with endogenous SLPI. Finally, we showed that phagocytosis of SLPI-coated mycobacteria was faster than that of uncoated bacteria. CONCLUSIONS: The present results demonstrate for the first time that human SLPI kills mycobacteria and is a new pattern recognition receptor for them.
